CSIMarket Company Name, Ticker, Industry, else..
 
Alvotech  (NASDAQ: ALVO)
 
Price: $5.0750 $-0.22 -4.064%
Day's High: $5.260000228881836 Week Perf: -2.22 %
Day's Low: $ 5.07 30 Day Perf: 24.08 %
Volume (M): 339,865 52 Wk High: $ 9.25
Volume (M$): $ 0 52 Wk Avg: $4.80
Open: $5.22 52 Wk Low: $2.94



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) -
 Employees 1,460
 Revenues (TTM) (Millions $) 589
 Net Income (TTM) (Millions $) 28
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 64

Business Description


Alvotech is a biopharmaceutical company specializing in the development, regulatory approval, and commercialization of biosimilar products. The company pursues regulatory approvals from agencies including the FDA, EMA, and MHRA, conducts clinical studies, and manages manufacturing and supply partnerships to support market introduction of its biosimilars.


   Company Address: 9 Luxembourg 1273
   Company Phone Number: 422 4500   Stock Exchange / Ticker: NASDAQ ALVO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
AMGN   -13.21%    
BCRX   -18.07%    
BIIB   -1.22%    
EXEL   -4.59%    
GILD   -3.88%    
HALO   -1.78%    
• View Complete Report
   



Announcement

Alvotech Secures Key Market Authorizations for Biosimilar Gobivaz as Industry Eyes Financial Results

Published Fri, Nov 7 2025 1:55 PM UTC

Reykjavik, Iceland and London, UK In a notable stride for the biosimilars industry, Alvotech, a global leader in the development and manufacture of biosimilar medicines, and its partner Advanz Pharma have successfully secured marketing authorizations from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Gobivaz, their biosimilar to Simponi (golimumab). ...
Announcement

Alvotech Under Investigation for Potential Securities Fraud as Company Engages with Investors

Published Wed, Nov 5 2025 10:26 AM UTC

New York-based Kirby McInerney LLP has announced an investigation into Alvotech, a biotechnology firm listed on NASDAQ under the ticker ALVO, for potential securities fraud. The law firm is scrutinizing whether Alvotech may have violated federal securities laws or participated in any other unlawful business activities.This investigation comes at a crucial time for Alvotech, ...
Announcement

Alvotech Prepares for Strategic Financial Update Amid Promising Industry Developments

Published Tue, Nov 4 2025 9:21 PM UTC

Alvotech (NASDAQ: ALVO), a leading global biotech company focused on developing and manufacturing biosimilar medicines, has recently made significant announcements concerning its financial performance and strategic engagements. As the company approaches its webcast and conference calls slated for November 2025, the market watches closely to assess the potential implications ...
Product Service News

Navigating the Regulatory Landscape Alvotechs Recent Developments with BIOSIMILARS

Published Mon, Nov 3 2025 10:04 AM UTC

In the dynamic realm of biopharmaceuticals, regulatory challenges and breakthroughs can dramatically reshape the landscape for companies involved in drug development. Alvotech, a global biotech company specializing in the manufacture of biosimilar medicines, recently encountered significant regulatory hurdles while also celebrating a notable success. This dual narrative offe...
Partnership

Alvotech Pioneers Biosimilar Advancements A Game Changer for Chronic Disease Treatment in Europe,

Published Mon, Sep 22 2025 8:53 AM UTC

The Rise of Biosimilars: Alvotech s Bold Stride into the European MarketIn an exciting development for the world of medicine, Alvotech, a prominent global biotech firm specializing in the development of biosimilars, has made significant strides in recent months, marking a pivotal moment for the pharmaceutical landscape in Europe. On September 22, 2025, Alvotech announced th...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.06
Working Capital Ratio 4.82
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) 0.21

Per Share Current
Earnings (TTM) 0 $
Revenues (TTM) -
Cash Flow (TTM) -
Cash -
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 403,359
Net Income per Employee (TTM) 19,123
Receivable Turnover Ratio (TTM) 7.42
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.4

Profitability Ratios Current
Gross Margin (MRQ) 60 %
Operating Margin (MRQ) 13.28 %
Net Margin (MRQ) 4.74 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) 79.52 %

Management Effectiveness Current
Return On Assets (TTM) 1.91 %
Return On Investment (TTM) 3.68 %
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Alvotech's Segments
Europe    52.17 % of total Revenue
USA    40.99 % of total Revenue
Rest of World    6.41 % of total Revenue
Customer A    27.13 % of total Revenue
Customer B    22.39 % of total Revenue
Customer C    22.36 % of total Revenue
Customer D    12.06 % of total Revenue
Customer E    6.25 % of total Revenue
Product and service revenue point in time revenue recognition Goods or services transferred at point in time    46.91 % of total Revenue
License revenue point in time revenue recognition Goods or services transferred at point in time    18.85 % of total Revenue
Performance revenue point in time revenue recognition Goods or services transferred at point in time    8.31 % of total Revenue
Development and other service revenue over time revenue recognition Goods or services transferred over time    25.49 % of total Revenue
Contract Assets    26.14 % of total Revenue
Contract Liabilities    -18.2 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.